- Home
- MDRR vs BLRX Comparison
MDRR vs BLRX Comparison
Compare MDRR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- BLRX
- Stock Information
- Founded
- MDRR 2015
- BLRX 2003
- Country
- MDRR United States
- BLRX Israel
- Employees
- MDRR N/A
- BLRX N/A
- Industry
- MDRR Real Estate Investment Trusts
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- BLRX Health Care
- Exchange
- MDRR Nasdaq
- BLRX Nasdaq
- Market Cap
- MDRR 17.1M
- BLRX 17.2M
- IPO Year
- MDRR 2018
- BLRX 2011
- Fundamental
- Price
- MDRR $13.44
- BLRX $3.75
- Analyst Decision
- MDRR
- BLRX Strong Buy
- Analyst Count
- MDRR 0
- BLRX 2
- Target Price
- MDRR N/A
- BLRX $19.00
- AVG Volume (30 Days)
- MDRR 6.5K
- BLRX 34.3K
- Earning Date
- MDRR 11-11-2025
- BLRX 08-14-2025
- Dividend Yield
- MDRR 1.95%
- BLRX N/A
- EPS Growth
- MDRR N/A
- BLRX N/A
- EPS
- MDRR N/A
- BLRX N/A
- Revenue
- MDRR $9,649,145.00
- BLRX $17,251,000.00
- Revenue This Year
- MDRR N/A
- BLRX N/A
- Revenue Next Year
- MDRR N/A
- BLRX N/A
- P/E Ratio
- MDRR N/A
- BLRX N/A
- Revenue Growth
- MDRR N/A
- BLRX 1.19
- 52 Week Low
- MDRR $9.55
- BLRX $2.30
- 52 Week High
- MDRR $15.00
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- MDRR 59.06
- BLRX 47.46
- Support Level
- MDRR $13.05
- BLRX $3.42
- Resistance Level
- MDRR $13.87
- BLRX $4.11
- Average True Range (ATR)
- MDRR 0.32
- BLRX 0.27
- MACD
- MDRR 0.04
- BLRX 0.05
- Stochastic Oscillator
- MDRR 61.83
- BLRX 35.11
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.